Certain Restricted Share Units of Legend Biotech Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2026.
Legend Biotech Corporation disclosed that certain restricted share units held by executive officers, directors, and a shareholder are under a 60-day lock-up ending 16 Aug 2026, starting 17 Jun 2026. After the lock-up, about 175 million ordinary shares (including ADSs) may enter public sale; total shares outstanding are 386,879,583.
How this was made
The 30-second read
Why it matters
As the lock-up ends, a large block of shares is expected to become eligible for public-market sale, raising near-term supply and potential volatility.
Market read
Traders can use the disclosed unlock date and estimated share availability to anticipate supply-driven price swings.
What to watch
Actual sell pressure depends on whether holders choose to sell immediately, broader market risk appetite, and any concurrent catalysts (trial updates, financing, or analyst actions) not mentioned here.
Background
The filing describes RSU and shareholder lock-up terms tied to a recent offering, including the 60-day restriction period.
Ticker impact
Legend Biotech RSUs are under a lock-up that ends 16-AUG-2026, with about 175M ordinary shares becoming available for sale after 60 days.
Mild-to-moderate downside risk into and shortly after 16-AUG-2026, with volatility likely highest near the unlock date.
The article discloses a defined lock-up end date and the scale of shares expected to become available for sale, which is directly relevant to supply/demand dynamics.
Market effects
Biopharma names with large insider or shareholder lock-ups can see similar supply-driven volatility around unlock dates.
Primarily US-listed small-to-mid cap biopharma liquidity dynamics; limited broader regional spillover expected.
Global cell-therapy peers may face sentiment spillover if investors generalize unlock-driven sell pressure across the sector.
Counterpoint
Unlocks do not always translate into selling; shares may be absorbed by demand, and selling could be spread out rather than concentrated on the exact date.
Key entities
- issuerLegend Biotech Corporation
Cell-therapy biopharmaceutical company whose RSUs and certain shareholders are subject to a lock-up ending 16-AUG-2026.
- product_candidateciltacabtagene autoleucel (cilta-cel)
Lead CAR-T cell therapy candidate referenced in the prospectus supplement background.
